Protalix BioTherapeutics (PLX) Tops Q1 EPS by 18c ; Offers Guidance
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.16 -2.7%
EPS Growth %: +400.0%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +400.0%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.22, $0.18 better than the analyst estimate of $0.04. Revenue for the quarter came in at $33.75 million versus the consensus estimate of $18.7 million.
GUIDANCE:
Protalix BioTherapeutics sees FY2026 revenue of $78-83 million, versus the consensus of $79.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- KeyCorp (KEY) files for 158.72M share offering by selling stockholders
- A.O. Smith executive chairman to retire, CEO to assume chairman role
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
